Arundathy Pandite Sells 30,000 Shares of Shattuck Labs (NASDAQ:STTK) Stock

Shattuck Labs, Inc. (NASDAQ:STTK) insider Arundathy Pandite sold 30,000 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $7.01, for a total transaction of $210,300.00. Following the sale, the insider owned 136,219 shares of the company’s stock, valued at approximately $954,895.19. This represents a 18.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shattuck Labs Stock Performance

NASDAQ STTK opened at $7.05 on Friday. The firm has a market cap of $540.59 million, a PE ratio of -11.19 and a beta of 1.05. Shattuck Labs, Inc. has a one year low of $0.71 and a one year high of $8.33. The firm’s fifty day moving average is $5.96 and its two-hundred day moving average is $5.27.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. During the same quarter last year, the company posted ($0.27) EPS. Research analysts predict that Shattuck Labs, Inc. will post -0.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on STTK shares. Cantor Fitzgerald began coverage on Shattuck Labs in a report on Monday, April 27th. They issued an “overweight” rating on the stock. Weiss Ratings raised Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Wedbush lifted their price objective on shares of Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Needham & Company LLC boosted their price objective on shares of Shattuck Labs from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Finally, Jefferies Financial Group upgraded shares of Shattuck Labs to an “outperform” rating and set a $7.00 price objective for the company in a research report on Friday, June 5th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Shattuck Labs currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Trading of Shattuck Labs

Several hedge funds have recently modified their holdings of the business. Aberdeen Group plc raised its position in Shattuck Labs by 462.1% in the fourth quarter. Aberdeen Group plc now owns 531,177 shares of the company’s stock worth $1,939,000 after acquiring an additional 436,673 shares in the last quarter. NEXTBio Capital Management LP purchased a new stake in shares of Shattuck Labs during the 4th quarter worth $11,497,000. Keel Point LLC acquired a new position in shares of Shattuck Labs during the 3rd quarter worth $110,000. Mallini Complete Financial Planning LLC acquired a new position in shares of Shattuck Labs during the 4th quarter worth $83,000. Finally, Pinnacle Associates Ltd. increased its holdings in shares of Shattuck Labs by 1.8% in the 3rd quarter. Pinnacle Associates Ltd. now owns 1,388,723 shares of the company’s stock valued at $3,319,000 after purchasing an additional 25,000 shares in the last quarter. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.